Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24966444 | 1.00 | L3MBTL1 (0.38) | L3MBTL1EPAS1MBTD1L3MBTL3NOS2 | |
| SCHEMBL30360171 | 0.93 | EPAS1 (0.41) | L3MBTL1EPAS1MBTD1L3MBTL3ALDH1A1 | |
| SCHEMBL21998829 | 0.93 | EPAS1 (0.41) | L3MBTL1EPAS1MBTD1L3MBTL3ALDH1A1 | |
| SCHEMBL14524889 | 0.90 | EPAS1 (0.40) | L3MBTL1EPAS1ALDH1A1PKM | |
| SCHEMBL16878061 | 0.89 | — | — | |
| SCHEMBL16763803 | 0.89 | L3MBTL1 (0.39) | L3MBTL1MBTD1L3MBTL3NOS2NOS3 | |
| SCHEMBL9595528 | 0.89 | L3MBTL1 (0.39) | L3MBTL1MBTD1L3MBTL3NOS2NOS3 | |
| SCHEMBL19853436 | 0.89 | L3MBTL1 (0.39) | L3MBTL1MBTD1L3MBTL3NOS2NOS3 | |
| SCHEMBL3814583 | 0.89 | — | — | |
| SCHEMBL19211543 | 0.89 | L3MBTL1 (0.39) | L3MBTL1MBTD1L3MBTL3NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2015103583-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2011000945-A2 | AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS | NENSIUS RESEARCH A/S (DK) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | MGAM, BPGM, MRPL21 | L3MBTL1 2869/4885EPAS1 3304/4885MBTD1 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.